Retatrutide
Triple receptor agonist (GLP-1/GIP/Glucagon) — most potent weight loss peptide in clinical trials.
What Is Retatrutide?
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — making it the first triple receptor agonist of its kind in advanced clinical development. Phase 2 trials have demonstrated average weight loss exceeding 24% over 48 weeks, surpassing all previously tested incretin-based therapies. It combines appetite reduction via GLP-1, enhanced fat burning through glucagon receptor activation, and metabolic optimization through GIP — addressing weight management through three distinct and complementary pathways.
Effectiveness Profile
Relative effectiveness scores derived from published preclinical literature across key endpoints.
Scores are qualitative aggregates from animal and in vitro studies and are not a medical claim. For educational purposes only.
Applications & Benefits
Effect Timeline
Expected milestones based on published preclinical data.
Simultaneous GLP-1, GIP, and glucagon receptor engagement. Early appetite suppression and energy expenditure increase detectable.
Faster onset than single/dual agonists due to glucagon component increasing metabolic rate. Significant appetite reduction.
Phase 2 trials showed average 17–24% weight loss. Visceral fat drops sharply; glucagon-driven thermogenesis contributes substantially.
Peak weight loss at ~24% average in clinical trials. Lean mass preservation through GIP receptor activity; metabolic rate elevated.
Simultaneous GLP-1, GIP, and glucagon receptor engagement. Early appetite suppression and energy expenditure increase detectable.
Faster onset than single/dual agonists due to glucagon component increasing metabolic rate. Significant appetite reduction.
Phase 2 trials showed average 17–24% weight loss. Visceral fat drops sharply; glucagon-driven thermogenesis contributes substantially.
Peak weight loss at ~24% average in clinical trials. Lean mass preservation through GIP receptor activity; metabolic rate elevated.
Timelines are derived from preclinical animal studies. Individual results in laboratory settings may vary. For educational purposes only.
Reconstitution Calculator
Calculate exact BAC water volume and dose measurements for Retatrutide.
For laboratory use only. This calculator is a reference tool — verify all calculations before use. Always use sterile technique with bacteriostatic water and sterile syringes.
Key Scientific Literature
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with obesity (PHASE 2)
Key finding: Phase 2 trial: up to 24.2% average weight loss at 48 weeks with 12 mg dose — highest ever recorded for an obesity pharmacotherapy.
Citations reference published peer-reviewed studies. This is not a complete literature review. All studies were conducted in preclinical or controlled clinical settings. Content is for educational reference only.
Related Topics
Retatrutide
For educational use only · Verified vendor
Quality Assurance
Related Guides
Tirzepatide
Dual GIP/GLP-1 receptor agonist studied for weight management and metabolic health.
MOTS-C
Mitochondria-derived peptide studied for metabolic regulation and longevity.
5-Amino-1MQ
NNMT inhibitor studied for fat loss, metabolism enhancement, and lean mass preservation.